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An orphan medicinal product, eculizumab is approved in Japan and globally for treating paroxysmal nocturnal
hemoglobinuria and atypical hemolytic uremic syndrome. Eculizumab therapy can cause late complement pathway
deficiencies that predispose patients to meningococcal infections. Although meningococcal vaccinations are
typically considered mandatory for eculizumab therapy, no approved vaccine is available in Japan as of March,
2014. Advertising unapproved, privately imported pharmaceuticals is prohibited under Japanese pharmaceutical
law; detailed information concerning the unapproved meningococcal vaccines is therefore not widely available.
The situation jeopardizes the safety of patients receiving eculizumab therapy, and Japanese clinicians are advised
caution when prescribing this therapy.
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The Japanese vaccine policy has been criticized for its lack
of a rational scientific approach [1]. The Japanese regula-
tory authority has its own policies for pharmaceutical regu-
latory reviews and approvals; the gap between Japan and
the United States (US) and the European Union regarding
approval of novel therapeutics has become a major issue in
Japan [2]. For example, the Japanese government conti-
nued to support use of a domestically manufactured oral
(live) polio vaccine until 2012, and only reluctantly permit-
ted importation of an inactivated polio vaccine from a
foreign manufacturer due to growing public criticism [3].
Although these issues have improved in recent years, a
number of vaccines approved in other countries remain
unavailable in Japan. Here we describe the problem of a
lack of approved meningococcal vaccines, which has led
to serious confusion among hematology and infectious
disease specialists, and has contributed to serious safety
concerns for patients in Japan.
An orphan medicinal product, eculizumab (Soliris,
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unless otherwise stated.hybrid IgG2/IgG4 monoclonal antibody directed against
human complement component C5; inhibition of comple-
ment activation at the level of C5 creates a functional
C5 deficiency [4]. The drug first obtained regulatory ap-
proval in the US in March 2007 to reduce hemolysis associ-
ated with paroxysmal nocturnal hemoglobinuria (PNH); in
September 2011, it was also approved for inhibition of
complement-mediated thrombotic microangiopathy in pa-
tients with atypical hemolytic uremic syndrome (aHUS) [5].
Eculizumab is currently approved globally; Japanese regula-
tory approvals were obtained in April 2010 and September
2013 for treatment of PNH and aHUS, respectively [6,7].
It should be noted that late complement pathway defi-
ciencies caused by eculizumab therapy predispose patients
to meningococcal infections due to the absence of menin-
gococcal lysis through classical and alternative pathways.
In clinical trials and extension studies of eculizumab in
PNH, two cases of meningococcal sepsis were reported
during treatment, an infection rate of 0.42 per 100 patient-
years [8]. Meningococcal infections can rapidly become
life-threatening or fatal without appropriate management.
Thus, it is essential to protect against meningococcal
disease by administering vaccines against Neisseria menin-
gitides to induce antibody-mediated killing of the micro-
organism. In prescribing information provided by the US
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http://www.ojrd.com/content/9/1/48recommend that clinicians “comply with the most current
Advisory Committee on Immunization Practices (ACIP)
recommendations for meningococcal vaccination in pa-
tients with complement deficiencies,” and “immunize pa-
tients with a meningococcal vaccine at least 2 weeks prior
to administering the first dose of Soliris, unless the risks
of delaying Soliris therapy outweigh the risks of developing
a meningococcal infection [5].” Similarly, in the summary
of product characteristics from the European Medicines
Agency, patients who are not currently vaccinated against
Neisseria meningitides are contraindicated to receive eculi-
zumab therapy; the Agency provides clear statements
that “to reduce the risk of infection, all patients must be
vaccinated at least 2 weeks prior to receiving Soliris. PNH
patients must be vaccinated 2 weeks prior to Soliris initi-
ation. aHUS patients who are treated with Soliris less
than 2 weeks after receiving a meningococcal vaccine
must receive treatment with appropriate prophylactic an-
tibiotics until 2 weeks after vaccination. Patients must
be re-vaccinated according to current medical guidelines
for vaccination use. Tetravalent vaccines against sero-
types A, C, Y and W135 are strongly recommended,
preferably conjugated ones [9].”
However, no recommendation for meningococcal vac-
cination appears in the Japanese package insert, although
a statement about the risk of meningococcal infection
appears in the boxed warnings [10]. This is because
there is no approved meningococcal vaccine in Japan as
of March 2014, and advertisement of unapproved phar-
maceuticals is prohibited under Japanese pharmaceutical
law. However, even in Japan, patients in eculizumab
clinical trials received meningococcal vaccination [6,7].
Therefore, it has become a common practice for Japanese
hematology specialists to provide unapproved, privately
imported meningococcal vaccines through travelers’
clinics for overseas tourists. This unofficial and un-
endorsed solution has caused confusion among physicians
and patients because detailed treatment information is not
shared through official routes. Although we had adminis-
tered dozens of meningococcal vaccinations to patients at
our travelers’ clinic, none of the physicians administering
eculizumab therapy provided information on which menin-
gococcal vaccine the patients should receive (polysac-
charide or polysaccharide-protein conjugate), the number
of doses, or at what intervals the patients should be re-
vaccinated. Furthermore, we have concerns about the costs
of unapproved vaccination (up to several hundred US
dollars), which are not compensated by the universal in-
surance coverage system. Considering the enormous fi-
nancial burden of eculizumab therapy, around 30,000 to
50,000 US dollars per month, it seems ironic that vacci-
nation is not compensated. The current Japanese vaccine
regulatory policy must be reformed as soon as possible, and
Japanese clinicians should adopt ACIP recommendationswithout age limitations for Japanese patients with persistent
complement component deficiencies that result from eculi-
zumab treatment [11].
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